Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Transportation to primary percutaneous coronary intervention, compared with on-site fibrinolysis, is a strong independent predictor of functional status after myocardial infarction: 5-year follow-up of the PRAGUE-2 trial

D. Mocova Bilkova, Z. Motovska, B. Prochazka, L. Groch, M. Zelizko, M. Aschermann, P. Widimsky, . ,

. 2014 ; 3 (2) : 105-9. (Acute cardiovascular care)

Language English Country England, Great Britain

Document type Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc15008461

AIMS: Subjective symptoms represent significant criteria of a patient's health condition; therefore, we focused on the long-term prevalence of heart failure symptoms and angina pectoris after myocardial infarction between two groups of patients in which two different therapeutic strategies were used during the acute phase of ST-elevation myocardial infarction (STEMI). METHODS: The PRAGUE-2 study enrolled 850 patients with STEMI. The patients were randomized into two groups - transport to a primary percutaneous coronary intervention (PCI) centre (n=429) vs. fibrinolysis in community hospitals (n=421). The data were collected from either primary hospitals or PCI centres, as well as via questionnaires. RESULTS: The mean follow-up was 58 months. At 5 years, 45.4% of patients were in New York Heart Association class I following primary PCI vs. 31.8% of those treated with fibrinolysis (OR 2.02, 95% CI 1.37-2.97, p<0.002). At 5 years, 83.6% of patients had no symptoms of angina pectoris following invasive therapy vs. 58% of patients treated with fibrinolysis (OR 4.47, 95% CI 2.79-7.18, p<0.001). CONCLUSIONS: The symptoms of angina pectoris and heart failure were significantly lower in patients assigned to primary PCI in the acute stage of myocardial infarction compared with patients treated with fibrinolysis at the 5-year follow up.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15008461
003      
CZ-PrNML
005      
20171127121809.0
007      
ta
008      
150306s2014 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1177/2048872613516016 $2 doi
035    __
$a (PubMed)24337919
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Mocova Bilkova, Dana $u Charles University, Prague, Czech Republic.
245    10
$a Transportation to primary percutaneous coronary intervention, compared with on-site fibrinolysis, is a strong independent predictor of functional status after myocardial infarction: 5-year follow-up of the PRAGUE-2 trial / $c D. Mocova Bilkova, Z. Motovska, B. Prochazka, L. Groch, M. Zelizko, M. Aschermann, P. Widimsky, . ,
520    9_
$a AIMS: Subjective symptoms represent significant criteria of a patient's health condition; therefore, we focused on the long-term prevalence of heart failure symptoms and angina pectoris after myocardial infarction between two groups of patients in which two different therapeutic strategies were used during the acute phase of ST-elevation myocardial infarction (STEMI). METHODS: The PRAGUE-2 study enrolled 850 patients with STEMI. The patients were randomized into two groups - transport to a primary percutaneous coronary intervention (PCI) centre (n=429) vs. fibrinolysis in community hospitals (n=421). The data were collected from either primary hospitals or PCI centres, as well as via questionnaires. RESULTS: The mean follow-up was 58 months. At 5 years, 45.4% of patients were in New York Heart Association class I following primary PCI vs. 31.8% of those treated with fibrinolysis (OR 2.02, 95% CI 1.37-2.97, p<0.002). At 5 years, 83.6% of patients had no symptoms of angina pectoris following invasive therapy vs. 58% of patients treated with fibrinolysis (OR 4.47, 95% CI 2.79-7.18, p<0.001). CONCLUSIONS: The symptoms of angina pectoris and heart failure were significantly lower in patients assigned to primary PCI in the acute stage of myocardial infarction compared with patients treated with fibrinolysis at the 5-year follow up.
650    _2
$a senioři $7 D000368
650    _2
$a koronární jednotky $x statistika a číselné údaje $7 D003325
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a komunitní nemocnice $x statistika a číselné údaje $7 D006764
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a infarkt myokardu $x patofyziologie $x terapie $7 D009203
650    _2
$a přemístění pacientů $x statistika a číselné údaje $7 D010360
650    _2
$a koronární angioplastika $x statistika a číselné údaje $7 D062645
650    _2
$a trombolytická terapie $x statistika a číselné údaje $7 D015912
650    _2
$a transport pacientů $x statistika a číselné údaje $7 D014187
650    _2
$a výsledek terapie $7 D016896
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Motovska, Zuzana
700    1_
$a Procházka, Bohumír, $d 1953-2017 $7 xx0075077
700    1_
$a Groch, Ladislav
700    1_
$a Zelizko, Michael
700    1_
$a Aschermann, Michael $7 nlk19990072993
700    1_
$a Widimsky, Petr
700    1_
$a ,
773    0_
$w MED00186154 $t European heart journal. Acute cardiovascular care. Acute cardiovascular care $x 2048-8734 $g Roč. 3, č. 2 (2014), s. 105-9
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24337919 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150306 $b ABA008
991    __
$a 20171127121935 $b ABA008
999    __
$a ok $b bmc $g 1065734 $s 891261
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 3 $c 2 $d 105-9 $i 2048-8734 $m European heart journal. Acute cardiovascular care $n Eur Heart J Acute Cardiovasc Care $x MED00186154 $o Acute cardiovascular care
LZP    __
$a Pubmed-20150306

Find record

Citation metrics

Archiving options